Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 12, 2017, Pages 2172-2177

  Bohl, Stephan R ^a   Kuchenbauer, Florian ^a   von Harsdorf, Stefanie ^a   Kloevekorn, Nadine ^a   Schönsteiner, Stefan S ^a   Rouhi, Arefeh ^a   Schwarzwälder, Phyllis ^a   Döhner, Hartmut ^a   Bunjes, Donald ^a   Bommer, Martin ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Alb Fils Hospital   (Germany)

Author keywords

Allogeneic stem cell transplantation; Thrombotic microangiopathy

Indexed keywords

CYCLOSPORIN; DEFIBROTIDE; ECULIZUMAB; EVEROLIMUS; HEMOGLOBIN; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VINCRISTINE; MONOCLONAL ANTIBODY; POLYDEOXYRIBONUCLEOTIDE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MALE; MANAGED CARE; MORTALITY RATE; MYCOSIS; OVERALL SURVIVAL; PATIENT RISK; PHARMACODYNAMICS; PLASMAPHERESIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ALLOTRANSPLANTATION; INFECTION; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INFECTION; MIDDLE AGED; POLYDEOXYRIBONUCLEOTIDES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85031304729     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.08.019     Document Type: Article

References (30)

1. Cho, B.S., Min, C.K., Eom, K.S., et al. Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (2008), 813–820.
2. Ho, V.T., Cutler, C., Carter, S., et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005), 571–575.
3. Jodele, S., Laskin, B.L., Dandoy, C.E., et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29 (2015), 191–204.
4. Jodele, S., Zhang, K., Zou, F., et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127 (2016), 989–996.
5. Arai, Y., Yamashita, K., Mizugishi, K., et al. Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 19 (2013), 1683–1689.
6. Obut, F., Kasinath, V., Abdi, R., Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant 51 (2016), 891–897.
7. Noris, M., Mescia, F., Remuzzi, G., STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8 (2012), 622–633.
8. Jodele, S., Davies, S.M., Lane, A., et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124 (2014), 645–653.
9. Vasu, S., Wu, H., Satoskar, A., et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 51 (2016), 1241–1244.
10. Loirat, C., Fakhouri, F., Ariceta, G., et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31 (2016), 15–39.
11. Jodele, S., Dandoy, C.E., Danziger-Isakov, L., et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant 22 (2016), 1337–1340.
12. Jodele, S., Dandoy, C.E., Myers, K.C., et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci 54 (2016), 181–190.
13. Jodele, S., Fukuda, T., Vinks, A., et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 20 (2014), 518–525.
14. de Fontbrune, F.S., Galambrun, C., Sirvent, A., et al. Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99 (2015), 1953–1959.
15. Cho, B.S., Yahng, S.A., Lee, S.E., et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 90 (2010), 918–926.
16. Jodele, S., Fukuda, T., Mizuno, K., et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 22 (2016), 307–315.
17. Cofiell, R., Kukreja, A., Bedard, K., et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 125 (2015), 3253–3262.
18. Cataland, S.R., Wu, H.M., Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 24 (2013), 486–491.
19. El-Bietar, J., Warren, M., Dandoy, C., et al. Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21 (2015), 1994–2001.
20. Uderzo, C., Bonanomi, S., Busca, A., et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82 (2006), 638–644.
21. Corti, P., Uderzo, C., Tagliabue, A., et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 29 (2002), 542–543.
22. Choi, C.M., Schmaier, A.H., Snell, M.R., Lazarus, H.M., Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 69 (2009), 183–198.
23. Kim, S.S., Patel, M., Yum, K., Keyzner, A., Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion 55 (2015), 452–458.
24. Fuge, R., Bird, J.M., Fraser, A., et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 113 (2001), 58–64.
25. Roy, V., Rizvi, M.A., Vesely, S.K., George, J.N., Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27 (2001), 641–646.
26. Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11 (2010), 785–797.
27. Benamu, E., Montoya, J.G., Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29 (2016), 319–329.
28. Noris, M., Galbusera, M., Gastoldi, S., et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124 (2014), 1715–1726.
29. Cugno, M., Gualtierotti, R., Possenti, I., et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12 (2014), 1440–1448.
30. Wehling, C., Amon, O., Bommer, M., et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 187 (2017), 304–315.